转移性激素敏感性前列腺癌全身治疗强化的成本效益:三联疗法是否具有成本效益?
该研究采用马尔可夫状态转换模型模拟新诊断转移性激素敏感性前列腺癌(mHSPC)男性的结局,从美国卫生部门视角以2022年美元计算成本。双联和三联治疗强化均较ADT单药改善质量调整生存,但仅多西他赛双联治疗在标准阈值下具有成本效益,增量成本效益比为13647美元。ARSLs需降价47%–70%才具有成本效益,仅药物成本影响模型结果。
要点
- 双联和三联治疗强化均较ADT单药改善质量调整生存。
- 仅多西他赛双联治疗在标准阈值下具有成本效益,ICER为13647美元。
- ARSLs需降价47%–70%才具有成本效益,仅药物成本影响模型结果。
核心结论
- 在mHSPC男性中,ARSLs治疗强化带来更好的质量调整生存,但按标准阈值不具有成本效益。
- 这些药物需大幅降价才具有成本效益,仿制药ARSLs一旦可用将使这些策略具有成本效益。
研究设计与样本
- 开发马尔可夫状态转换模型模拟新诊断mHSPC男性的结局,患者进入模型时为mHSPC疾病状态,随后进展为去势抵抗性疾病并最终死于前列腺癌。
- 成本从美国卫生部门视角以2022年美元计算,并进行确定性和概率敏感性分析以考虑参数估计的不确定性。
- 还对英国和澳大利亚卫生部门的成本进行了情景分析。
主要发现
- 双联和三联治疗强化均较ADT单药改善质量调整生存。
- 仅多西他赛双联治疗在标准阈值下具有成本效益,增量成本效益比为13647美元。
- ARSLs需降价47%–70%才具有成本效益。
- 仅药物成本影响模型结果;若使用阿比特龙醋酸酯的仿制药价格,则阿比特龙三联治疗是最具价值的选择。
- 英国和澳大利亚卫生部门分析获得相似结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There has been a shift toward systemic treatment intensification for men with metastatic hormone-sensitive prostate cancer (mHSPC). Recent trials have demonstrated the efficacy of triplet therapy with an androgen receptor signalling inhibitor (ARSI), docetaxel, and androgen deprivation therapy (ADT). However, ARSI treatment is expensive. The objective was to determine the cost effectiveness of current treatments strategies for men with mHSPC. METHODS: We developed a Markov state-transition model to simulate outcomes for men with newly diagnosed mHSPC. For the simulation, patients were entered in the model in the mHSPC disease state before progressing to castration-resistant disease and finally dying from prostate cancer. Costs were calculated from a USA health sector perspective in 2022 US dollars. Deterministic and probabilistic sensitivity analyses were conducted to account for uncertainty in the parameter estimates. We also performed scenario analyses for costs in the UK and Australian health sectors. KEY FINDINGS AND LIMITATIONS: Treatment intensification with doublet and triplet therapy resulted in an improvement in quality-adjusted survival for all strategies in comparison to ADT monotherapy. However, only docetaxel doublet therapy was cost effective at standard thresholds, with an incremental cost-effectiveness ratio of $13 647. The cost of ARSIs needed to be discounted by 47-70% before they were cost effective. Only medication costs impacted the model results. If the generic price for abiraterone acetate is used, then triplet therapy with abiraterone is the best-value option. Similar results were obtained for analyses for the UK and Australian health sectors. CONCLUSIONS AND CLINICAL IMPLICATIONS: Treatment intensification with ARSIs in men with mHSPC results in better quality-adjusted survival but is not cost effective according to standard thresholds. The costs of these medications would need to be heavily discounted before they are cost effective. The cost of generic ARSIs, once available, would render these strategies cost effective. PATIENT SUMMARY: This report examines whether increasing the number of systemic drugs used to treat a patient's metastatic hormone-sensitive prostate cancer is cost effective for the health care system. We found that the additional cost of triplet therapy does not justify the increase in patient benefit.
引用
- Sathianathen NJ, Lawrentschuk N, Konety B, et al. Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective? Eur Urol Oncol. 2023. PMID: 38057191. doi:10.1016/j.euo.2023.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。